Found: 11
Select item for more details and to access through your institution.
LOXO-305, A Next Generation Reversible BTK Inhibitor, for Overcoming Acquired Resistance to Irreversible BTK Inhibitors.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2018, v. 18, p. S216, doi. 10.1016/j.clml.2018.07.081
- By:
- Publication type:
- Article
Inhibition of mutant EGFR in lung cancer cells triggers SOX2-FOXO6-dependent survival pathways.
- Published in:
- eLife, 2015, p. 1, doi. 10.7554/eLife.06132.001
- By:
- Publication type:
- Article
Response to the Selective RET Inhibitor Selpercatinib (LOXO-292) in a Patient With RET Fusion-positive Atypical Lung Carcinoid.
- Published in:
- Clinical Lung Cancer, 2021, v. 22, n. 3, p. e442, doi. 10.1016/j.cllc.2020.06.011
- By:
- Publication type:
- Article
FGFR2 signaling underlies p63 oncogenic function in squamous cell carcinoma.
- Published in:
- Journal of Clinical Investigation, 2013, v. 123, n. 8, p. 3525, doi. 10.1172/JCI68899
- By:
- Publication type:
- Article
The molecular pathogenesis of head and neck squamous cell carcinoma.
- Published in:
- 2012
- By:
- Publication type:
- journal article
The molecular pathogenesis of head and neck squamous cell carcinoma.
- Published in:
- Journal of Clinical Investigation, 2012, v. 122, n. 6, p. 1951, doi. 10.1172/JCI59889
- By:
- Publication type:
- Article
A microRNA-dependent program controls p53-independent survival and chemosensitivity in human and murine squamous cell carcinoma.
- Published in:
- 2011
- By:
- Publication type:
- journal article
Mutation frequency in 15 common cancer genes in high-risk head and neck squamous cell carcinoma.
- Published in:
- Head & Neck, 2014, v. 36, n. 8, p. 1181, doi. 10.1002/hed.23430
- By:
- Publication type:
- Article
Response to RET-Specific Therapy in RET Fusion-Positive Anaplastic Thyroid Carcinoma.
- Published in:
- Thyroid, 2020, v. 30, n. 9, p. 1384, doi. 10.1089/thy.2019.0477
- By:
- Publication type:
- Article
A Novel ALK Fusion in Pediatric Medullary Thyroid Carcinoma.
- Published in:
- Thyroid, 2019, v. 29, n. 11, p. 1704, doi. 10.1089/thy.2019.0041
- By:
- Publication type:
- Article
EGFR and EphA2 are host factors for hepatitis C virus entry and possible targets for antiviral therapy.
- Published in:
- Nature Medicine, 2011, v. 17, n. 5, p. 589, doi. 10.1038/nm.2341
- By:
- Publication type:
- Article